NDAINTRACAVITARY, INTRAVENOUS, INTRAVESICALPOWDER
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
Alkylating Activity
Pharmacologic Class:
Alkylating Drug
Clinical Trials (1)
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
Started Mar 2005
37 enrolled
Lymphoma
Loss of Exclusivity
LOE Date
May 31, 2037
136 months away
Patent Expiry
May 31, 2037
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 9931458 | May 31, 2037 | Product | — |